WO2022224274A1 - Polymorphic forms of sacubitril-telmisartan (1:1) - Google Patents
Polymorphic forms of sacubitril-telmisartan (1:1) Download PDFInfo
- Publication number
- WO2022224274A1 WO2022224274A1 PCT/IN2022/050374 IN2022050374W WO2022224274A1 WO 2022224274 A1 WO2022224274 A1 WO 2022224274A1 IN 2022050374 W IN2022050374 W IN 2022050374W WO 2022224274 A1 WO2022224274 A1 WO 2022224274A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sacubitril
- telmisartan
- solvent
- amorphous
- crystalline form
- Prior art date
Links
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title claims abstract description 169
- 229960005187 telmisartan Drugs 0.000 title claims abstract description 169
- 239000007962 solid dispersion Substances 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 62
- 239000002904 solvent Substances 0.000 claims description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 36
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 229960003953 sacubitril Drugs 0.000 claims description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 17
- 238000001144 powder X-ray diffraction data Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 11
- 239000012454 non-polar solvent Substances 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 229920003072 Plasdone™ povidone Polymers 0.000 claims description 7
- 229920003081 Povidone K 30 Polymers 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 239000002798 polar solvent Substances 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 6
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960004592 isopropanol Drugs 0.000 claims 6
- -1 glidants Substances 0.000 description 14
- 229920013820 alkyl cellulose Polymers 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 239000003911 antiadherent Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229940080350 sodium stearate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 1
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- PYNXFZCZUAOOQC-UHFFFAOYSA-N 4-[[5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid Chemical compound C1=CC(CC(CC(C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 235000019886 MethocelTM Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- CMCJFUXWBBHIIL-UHFFFAOYSA-N Propylene glycol stearate Chemical class CC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CMCJFUXWBBHIIL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229940100321 entresto Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000673 poly(carbodihydridosilane) Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention provides polymorphic forms of Sacubitril-Telmisartan and amorphous solid dispersion.
- Sacubitril chemically known as 4-[[ -l-(biphenyl-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl] amino] -4-oxobutanoic acid represented in Formula I;
- Telmisartan chemically known as 4'-[2-n-propyl-4-methyl-6-(l-methylbenzimid-azol-2- yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid are represented in Formula II.
- Sacubitril and its pharmaceutically acceptable salts thereof is known in US 5,217,996.
- Telmisartan product is known in the US 5,591,762 and Telmisartan Form A is known in US 6,358,986 Bl.
- the supramolecular complex of Sacubitril and valsartan is known in the US 8,877,938 patent. The patent discloses the supramolecular complex in form of trisodium Sacubitril-valsartan hemipentahydrate .
- the principal object of the present invention is to provide crystalline and amorphous form, amorphous solid dispersion of Sacubitril-Telmisartan and also process for the preparation of the same.
- the present invention provides an amorphous form of Sacubitril-Telmisartan
- the present invention provides an amorphous solid dispersion of Sacubitril- Telmisartan (1:1).
- the present invention provides a process for the preparation of amorphous form of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril and Telmisartan in a suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous Sacubitril-Telmisartan.
- the present invention provides a process for the preparation of an amorphous solid dispersion of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril; Telmisartan and a pharmaceutically acceptable excipient in suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous solid dispersion of Sacubitril-Telmisartan
- the present invention provides crystalline form I of Sacubitril-Telmisartan.
- the present invention also provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril-Telmisartan into a suitable solvent or mixtures thereof; and b) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
- the present invention also provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril-Telmisartan in a first solvent; and b) optionally seeding with crystalline Form I seeds of Sacubitril-Telmisartan; c) adding a second solvent; and d) filtering to isolate crystalline form I of Sacubitril-Telmisartan.
- FIGURE 1 PXRD pattern of amorphous form of Sacubitril-Telmisartan obtained as per Example 1.
- FIGURE 2 PXRD pattern of amorphous form of Sacubitril-Telmisartan obtained as per Example 2.
- FIGURE 3 PXRD pattern of amorphous solid dispersion of Sacubitril-Telmisartan obtained as per Example 3.
- FIGURE 4 PXRD pattern of amorphous solid dispersion of Sacubitril-Telmisartan obtained as per Example 4.
- FIGURE 5 PXRD pattern of amorphous solid dispersion of Sacubitril-Telmisartan obtained as per Example 5.
- FIGURE 6 PXRD pattern of crystalline form I of Sacubitril-Telmisartan obtained as per Example 6.
- FIGURE 7 PXRD pattern of crystalline form I of Sacubitril-Telmisartan obtained as per Example 7.
- FIGURE 8 Modulated DSC plot of Sacubitril-Telmisartan (1:1) Amorphous Form.
- FIGURE 9 DSC thermogram of crystalline Sacubitril-Telmisartan (1:1) Form I.
- FIGURE 10 TGA/DTA analysis of crystalline Sacubitril-Telmisartan (1:1) Form I.
- FIGURE 11 FT-IR spectra of Sacubitril.
- FIGURE 12 FT-IR spectra of Telmisartan Form A.
- FIGURE 13 FT-IR spectra of amorphous Sacubitril-Telmisartan.
- FIGURE 14 FT-IR spectra of crystalline Form I Sacubitril-Telmisartan.
- the principal object of the present invention is to provide processes for the preparation of crystalline form I and an amorphous form of Sacubitril-Telmisartan; amorphous solid dispersion of Sacubitril-Telmisartan and process for the preparation of the same.
- Powder X-ray Diffraction The X-ray diffraction patterns of said polymorphs of the present invention were measured on BRUKER D8 Discover powder diffractometer equipped with goniometer of Q/2Q configuration and Lynx Eye detector. The Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 2Q range of 2.0°— 50.0°, 0.030° step size and 0.4 seconds step time.
- MDSC Powder X-ray Diffraction
- T g glass transition temperature
- DSC was recorded using TA Q5000 of TA instruments. The experiments were performed at a heating rate of 10.0°C/min over a temperature range of 20°C— 300°C purging with nitrogen at a flow rate of 50 ml/min. Standard aluminum pans covered by lids with five pinholes were used.
- TGA was recorded using TA Q5000 of TA instruments. The experiments were performed at a heating rate of 10.0°C/min over a temperature range of 20°C-300°C purging with nitrogen at a flow rate of 25 ml/min. Standard aluminum pans covered by lids with five pin holes were used.
- the FT-IR data was recorded using Perkin Elmer spectrum one instrument in the range of 400- 4000 cm 1 by using KBr pellets.
- Sacubitril-Telmisartan of the present invention is as shown below is a complex of Sacubitril-Telmisartan (1:1).
- the amorphous solid dispersion of Sacubitril-Telmisartan is a complex of Sacubitril- Telmisartan and an excipient (1:1).
- the present invention is directed to dual-acting compound where it constituent Sacubitril and Telmisartan molecules are linked via non-covalent bonding, or a supramolecular complex comprising said molecules, also described as mixed salts or cocrystals, depending on the degree of transfer of the proton from the proton donor to the acceptor, linking the two constituent molecules by hydrogen bonding — known examples of such multi-drug, fixed dose combination products being Entresto (valsartan-Sacubitril) and Seglentis (1:1 tramadol hydrochloride-celecoxib complex) .
- the present invention provides amorphous form of Sacubitril-Telmisartan.
- One embodiment of this invention is a solid phase comprising a 1:1 amorphous complex of Sacubitril and Telmisartan, characterized by a single glass transition in modulated DSC, a distinct halo-like PXRD pattern indicating an amorphous phase and significant shifts in the IR absorption bands compared to the constituent molecules- corresponding to strong hydrogen bonding interactions.
- the amorphous form of Sacubitril-Telmisartan disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.l & FIG 2.
- the present invention provides a process for the preparation of amorphous form of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril and Telmisartan in a suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous Sacubitril-Telmisartan.
- Sacubitril and Telmisartan are dissolved in a suitable solvent or mixtures thereof.
- the suitable solvent for dissolving includes, but not limited to polar solvents and non-polar solvents.
- Polar solvents such as methanol, ethanol, propanol, isopropanol, butanol, trifluroethanol, hexafluro-2-propanol, water, dimethyl sulfoxide and non polar solvents such as dichloromethane, toluene.
- mixture of solvents more preferably mixture of methanol and dichloromethane.
- the suitable temperature for dissolving is selected from 20-35°C; preferably 23-27 °C.
- the solvent is removed from the above resulting Sacubitril-Telmisartan solution to isolate amorphous Sacubitril-Telmisartan.
- the solvent removal of the above embodiment may carry out according to the methods well known in the art, for example, by distillation, evaporation, spray drying, lyophilization, freeze drying or by agitated thin film drier.
- the present invention provides a process for the preparation of amorphous solid dispersion of Sacubitril-Telmisartan.
- the pharmaceutical excipient for the solid dispersion of Sacubitril- Telmisartan may include diluents, lubricants, binders, glidants, stabilizers, surface active agents, anti- adherents, opacifiers, solvents, colorants, lubricants, pigments, anti-foam agents, and polishing agents.
- microcrystalline cellulose, polysorbate, mannitol, and hydroxypropyl alkylcellulose, hydroxypropyl alkylcellulose acetate succinate, hydroxypropyl alkylcellulose acetate succinate L-type M-type and H-type grades are found to be particularly useful excipients.
- the excipient or combinations of excipients may be included in the formulation.
- the preferable pharmaceutical excipients for the amorphous solid dispersion of Sacubitril-Telmisartan is ethyl cellulose, Plasdone S-630 and Povidone-K30.
- the amorphous solid dispersion of Sacubitril-Telmisartan and ethyl cellulose disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.3.
- the amorphous solid dispersion of Sacubitril-Telmisartan and Plasdone S- 630 disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.4.
- the amorphous solid dispersion of Sacubitril-Telmisartan and Povidone- K30 disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.
- the present invention provides a process for the preparation of amorphous solid dispersion of Sacubitril-Telmisartan (1:1).
- the present invention provides a process for the preparation of an amorphous solid dispersion of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril; Telmisartan and a pharmaceutically acceptable excipient in suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous solid dispersion of Sacubitril-Telmisartan
- Sacubitril; Telmisartan and a pharmaceutically acceptable excipient are dissolved in a suitable solvent or mixtures thereof.
- the suitable solvent for dissolving includes, but not limited to polar solvents and non-polar solvents.
- Polar protic solvents such as methanol, ethanol, trifluroethanol, hexafluro-2-propanol, propanol, isopropanol, butanol, water, dimethyl sulfoxide and non-polar solvents such as dichloromethane, toluene, preferably mixture of solvents; more preferably mixture of methanol and dichloromethane.
- the suitable temperature for dissolving is selected from 20- 35°C; preferably 23-27 °C.
- the pharmaceutical excipient may include diluents, lubricants, binders, glidants, stabilizers, surface active agents, anti-adherents, opacifiers, solvents, colorants, lubricants, pigments, anti-foam agents, and polishing agents.
- microcrystalline cellulose, polysorbate, mannitol, and hydroxypropyl alkylcellulose, hydroxypropyl alkylcellulose acetate succinate, hydroxypropyl alkylcellulose acetate succinate L-type, M-type and H-type grades are found to be particularly useful excipients.
- the excipient or combinations of excipients may be included in the formulation.
- Examples of useful pharmaceutical excipients within the context of the present invention include starches, lactose, mannitol (for example, PearlitolTM SD200), cellulose and cellulose derivatives, and confectioner's sugar.
- lactose may be useful in the context of the present invention, for example, lactose monohydrate, lactose DT (direct tableting), and lactose anhydrous.
- starches may be used in the context of the present invention, for example, maize starch, potato starch, rice starch, wheat starch, pre-gelatinized starch, starch 1500, starch 1500 LM grade, and fully pre-gelatinized starch.
- Suitable cellulose compounds for use in the context of the present invention include crystalline celluloses, such as CeolusTM KG-801, and a variety of AvicelTM celluloses (for example, PH- 101, PH-102, PH-301, PH-302, PH-F20, PHI-12, PH-114, and PH-112). Powdered celluloses may be used as well.
- HPC examples include Klucel TM LF and KlucelTM EXF
- L-HPCS examples include LH-11, LH-21, LH-31, LH-22, LH-32, LH-20, LH-30, LH-32 and LH-33
- HPMC hydroxypropyl alkyl cellulose
- HPMC-AS hydroxypropyl alkylcellulose acetate succinate including L-type M-type and H-type grades
- binders/disintegrants include polyvinylpyrrolidones (also called povidone; examples include PVP-K25, PVP-K29, PVP- K30, and PVP-K90), copovidone (for example, PlasdoneTM S-630).
- polyvinylpyrrolidones also called povidone; examples include PVP-K25, PVP-K29, PVP- K30, and PVP-K90
- copovidone for example, PlasdoneTM S-630.
- excipients include powdered acacia, gelatin, guar gum, sodium starch glycolate, colloidal silicon dioxide, carbomers (for example, CarbopolTM), alkylcelluloses, polymethacrylates, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, and crospovidones (for example, cross- linked povidone, KollidonTM CL PolyplasdoneTM XL, XI- 10, and INF- 10).
- carbomers for example, CarbopolTM
- alkylcelluloses for example, alkylcelluloses, polymethacrylates
- carmellose calcium for example, carboxymethyl starch sodium, croscarmellose sodium, and crospovidones
- cross- linked povidone KollidonTM CL PolyplasdoneTM XL, XI- 10, and INF- 10
- excipients include sorbitan esters (for example, SpanTM), polyhydroxyethylenically- treated sorbitan esters (for example, TweenTM), aliphatic alcohols and polyethylene glycol (PEG) ethers, phenol and PEG ethers, quaternary ammonium salts (e.g., cetyltrimethylammonium bromide), amine salts (for example, octadecylamine Hydrochloride), stearates (for example, glyceryl monostearates, polyoxyethylene mono stearates, ethylene glycol stearates, propylene glycol stearates, diethylene glycol stearates, glycerol stearates, sodium stearate, potassium stearate, ammonium stearate, calcium stearate, sodium stearate, triethenolamine stearate, zinc stearate, and magnesium stearate),
- Phospholipids e.g., diacylphosphatidylglycerols, diaceylphosphatidylcholines, and diaceylphosphatidic acids, the precursors and derivatives thereof, such as soybean lecithin and egg yolk
- suitable pigments include titanium oxide, silicon dioxide, iron oxides, zinc oxide, and combinations thereof.
- Suitable plasticizers include, as examples, castor oil, diacetylated mono glycerides, dibutyl sebacate, diethyl phthalate, glycerin, polyethylene glycol, polyethylene glycol 6000, stearic acid, propylene glycol, triacetin, and triethyl citrate.
- Suitable basic inorganic salts of sodium, potassium, magnesium, and calcium e.g., sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium carbonate, calcium carbonate, magnesium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, potassium hydrogen carbonate, potassium hydroxide, heavy magnesium carbonate, magnesium, [Mg6Al(0H)16 C03-4H20], aluminum hydroxide-magnesium, and [2.5MgO ⁇ A1203 ⁇ 20] may be include in the formulation as well.
- excipients listed above can act in a multitude of functional roles (e.g., starches can act both as a disintegrates and a binder depending on the formulation) to dictate the final properties of the desired product.
- functional roles e.g., starches can act both as a disintegrates and a binder depending on the formulation
- One of skill in the art will readily recognize these various functional aspects of each excipient and be able to incorporate, without undue experimentation, an excipient, or combinations of excipients to achieve the desired final product.
- ethyl cellulose, Plasdone S-630 and Povidone-K30 have been found to particularly useful excipients for preparing an amorphous solid dispersion of Sacubitril and Telmisartan.
- the solvent is removed from the above resulting Sacubitril-Telmisartan solution to isolate amorphous Sacubitril-Telmisartan solid dispersion.
- the solvent removal of the above embodiment may carried out according to the methods well known in the art, for example, by distillation, evaporation, spray drying, lyophilization, freeze drying or by agitated thin film drier.
- the present invention provides crystalline form I of Sacubitril- Telmisartan.
- Yet another embodiment of this invention is a 1:1 crystalline complex of Sacubitril and Telmisartan designated as Form I, characterized by a single melting endotherm in DSC and a crystalline PXRD pattern, both distinct from either of the constituent molecules and significant shifts in the IR absorption bands compared to the constituent molecules-corresponding to strong hydrogen bonding interactions, and containing water in the range of 1.5% to 2.5% indicating that it is a hydrate, preferably a monohydrate.
- the crystalline form I of Sacubitril-Telmisartan disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.6 & FIG.7.
- the crystalline form I of Sacubitril-Telmisartan disclosed herein may be characterized by PXRD spectrum having peaks 4.50, 16.53, 20.09, 24.32, 24.74 ⁇ 0.2° 2Q.
- the crystalline form I of Sacubitril-Telmisartan disclosed herein may be further characterized by PXRD spectrum having peaks 4.50, 12.78, 16.53, 18.95, 20.09, 20.97, 24.32, 24.74, 25.71 ⁇ 0.2° 2Q.
- the present invention also provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril-Telmisartan into a suitable solvent or mixtures thereof; and b) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
- the Sacubitril-Telmisartan is taken into suitable solvent or mixtures thereof.
- the Sacubitril-Telmisartan of this embodiment may in an amorphous form and may further dissolved or suspended in suitable solvent or mixtures thereof.
- the suitable solvent for the dissolution or suspension is selected from organic solvents, but not limited to non-polar solvents such as diethyl ether, isopropyl ether, methyl tertiary butyl ether, cylcopentyl methyl ether, toluene, xylene or mixtures thereof.
- the reaction is maintained at 0 °C to reflux temperature, preferably at room temperature.
- the reaction mixture is stirred for 30 min to-24 hrs; preferably 1-5 hrs; more preferably 2-3 hrs.
- the solvent is removed by filtering from the above resulting Sacubitril-Telmisartan mixture to isolate the solid of Sacubitril-Telmisartan.
- the solid may be further processed by drying to obtain crystalline form I of Sacubitril-Telmisartan.
- the present invention also a provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril-Telmisartan into a first solvent or mixtures thereof; and b) optionally seeding with crystalline Form I seeds of Sacubitril-Telmisartan; c) adding a second solvent; and d) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
- the Sacubitril-Telmisartan is dissolved into suitable first solvent and optionally seeded with Form I seeds and further added a second solvent and maintained the reaction for completion. After completion of the reaction, the reaction mass was filtered to isolate crystalline Form I of Sacubitril-Telmisartan.
- suitable first and second solvents are selected from organic solvents.
- the first solvent is selected from alcoholic solvents such as methanol, ethanol, propanol, isopropanol; halogenated solvents selected from dichloromethane, trifluroethanol, trichloro ethanol, and hexafluroisopropanol.
- the second solvents selected from non-polar solvents such heptane, diethyl ether, isopropyl ether, cylcopentyl methyl ether; preferably; the suitable first solvent is dichloromethane and the second solvent is heptane.
- the reaction is maintained at 0 °C to reflux temperature, preferably at room temperature.
- the reaction mixture is stirred for 30 min to-24 hrs; preferably 1-5 hrs; more preferably 2-3 hrs.
- Sacubitril-Telmisartan of this embodiment may in an amorphous form and may further dissolved or suspended in suitable solvent or mixtures thereof.
- the solvent is removed by filtering from the above resulting Sacubitril-Telmisartan mixture to isolate the solid of Sacubitril-Telmisartan.
- the solid may be further processed by drying to obtain crystalline form I of Sacubitril-Telmisartan.
- DSC overlay ( Figure 9) of crystalline Sacubitril-Telmisartan (1:1) Form I shows one endothermic peak at about 88°C.
- the later events seen in the thermogram of crystalline Sacubitril-Telmisartan (1:1) Form I may be attributed to the recrystallization of Telmisartan Form A.
- Sacubitril-Telmisartan (1:1) amorphous form and crystalline Sacubitril-Telmisartan (1:1) Form I were analyzed for water content by Karl-Fischer (KF) titration. The results are summarized in Table 1.
- Sacubitril-Telmisartan (1:1) amorphous form and crystalline Sacubitril-Telmisartan (1:1) Form I are novel complexes.
- the crystalline Sacubitril-Telmisartan (1:1) Form I is a hydrate, preferably a monohydrate.
- Sacubitril-Telmisartan (1:1) amorphous form was determined by storing the samples at 5 ⁇ 3°C and 25°C and 60% relative humidity (RH) conditions for 9 months and the samples were analyzed by PXRD and HPLC Purity. The results are shown in below Table 3A.
- the Sacubitril-Telmisartan (1:1) amorphous form was found to be physically and chemically stable at 5 ⁇ 3°C and 25°C and 60% relative humidity (RH) conditions upto nine months.
- the physical and chemical stability of crystalline Sacubitril- Telmisartan (1:1) Form I was determined by storing the samples at 5 ⁇ 3°C and 25°C and 60% relative humidity (RH) conditions for 3 months and the samples were analyzed by PXRD and HPLC Purity. The results are shown in below Table 3B.
- the crystalline Sacubitril-Telmisartan (1:1) Form I was found to be physically and chemically stable at 5 ⁇ 3°C and 25°C and 60% relative humidity (RH) conditions upto three months.
- Example 3 Amorphous solid dispersion of Sacubitril-Telmisartan (1:1):
- Example 4 Amorphous solid dispersion of Sacubitril-Telmisartan (1:1):
- Example 8 Crystalline Form I of Sacubitril-Telmisartan (1:1):
- Sacubitril-Telmisartan amorphous form 100 mg was dissolved in 1 mL xylene at 25 ⁇ 2°C. Stir the reaction mass at 25 ⁇ 2°C for 2 h. The product obtained was filtered and suck-dried for 30 minutes to yield novel crystalline Sacubitril-Telmisartan Form I. Yield: 80 mg.
- Sacubitril-Telmisartan amorphous form 50 g was dissolved in 150 mL of dichloromethane at 25 ⁇ 2°C and cooled to 2 ⁇ 2°C, then added 2.5g of Sacubitril-Telmisartan Form I seeds and added 1L of n-heptane at 2 ⁇ 2°C for 40 minutes.
- the reaction mass was maintained under stirring at 2 ⁇ 2°C for 17 h, filtered, washed with 100 mL of chilled heptane and dried under vacuum at 50 °C for 48h.
- the resulting solid was identified as novel crystalline Sacubitril- Telmisartan Form I. Yield: 48.8 g.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides polymorphic forms namely crystalline Form I, amorphous form and amorphous solid dispersions of Sacubitril-Telmisartan. It also provides process for the preparation of the same.
Description
POLYMORPHIC FORMS OF SACUBITRIL-TELMISARTAN (1:1)
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is cognate of earlier filed of Indian Provisional Patent Application No.’s IN202141018214 filed on April 20, 2021 and IN202141026619 filed on June 15, 2021.
FIELD OF THE INVENTION
The present invention provides polymorphic forms of Sacubitril-Telmisartan and amorphous solid dispersion.
BACKGROUND OF THE INVENTION
Sacubitril, chemically known as 4-[[ -l-(biphenyl-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl] amino] -4-oxobutanoic acid represented in Formula I;
Telmisartan, chemically known as 4'-[2-n-propyl-4-methyl-6-(l-methylbenzimid-azol-2- yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid are represented in Formula II.
Formula P
Sacubitril and its pharmaceutically acceptable salts thereof is known in US 5,217,996. Telmisartan product is known in the US 5,591,762 and Telmisartan Form A is known in US 6,358,986 Bl.
The supramolecular complex of Sacubitril and valsartan is known in the US 8,877,938 patent. The patent discloses the supramolecular complex in form of trisodium Sacubitril-valsartan hemipentahydrate .
OBJECT AND SUMMARY OF THE INVENTION
The principal object of the present invention is to provide crystalline and amorphous form, amorphous solid dispersion of Sacubitril-Telmisartan and also process for the preparation of the same.
In another aspect, the present invention provides an amorphous form of Sacubitril-Telmisartan
(1:1).
In one more aspect, the present invention provides an amorphous solid dispersion of Sacubitril- Telmisartan (1:1).
In another aspect, the present invention provides a process for the preparation of amorphous form of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril and Telmisartan in a suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous Sacubitril-Telmisartan.
In one more aspect, the present invention provides a process for the preparation of an amorphous solid dispersion of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril; Telmisartan and a pharmaceutically acceptable excipient in suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous solid dispersion of Sacubitril-Telmisartan
In another aspect, the present invention provides crystalline form I of Sacubitril-Telmisartan.
In one more aspect, the present invention also provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril-Telmisartan into a suitable solvent or mixtures thereof; and b) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
In another aspect, the present invention also provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril-Telmisartan in a first solvent; and b) optionally seeding with crystalline Form I seeds of Sacubitril-Telmisartan; c) adding a second solvent; and d) filtering to isolate crystalline form I of Sacubitril-Telmisartan.
BRIEF DESCRIPTION OF THE DRAWINGS
Further aspects of the present disclosure together with additional features contributing thereto and advantages accruing therefrom will be apparent from the following description of embodiments of the disclosure which are shown in the accompanying figures wherein:
FIGURE 1: PXRD pattern of amorphous form of Sacubitril-Telmisartan obtained as per Example 1.
FIGURE 2: PXRD pattern of amorphous form of Sacubitril-Telmisartan obtained as per Example 2.
FIGURE 3: PXRD pattern of amorphous solid dispersion of Sacubitril-Telmisartan obtained as per Example 3.
FIGURE 4: PXRD pattern of amorphous solid dispersion of Sacubitril-Telmisartan obtained as per Example 4. FIGURE 5: PXRD pattern of amorphous solid dispersion of Sacubitril-Telmisartan obtained as per Example 5.
FIGURE 6: PXRD pattern of crystalline form I of Sacubitril-Telmisartan obtained as per Example 6.
FIGURE 7: PXRD pattern of crystalline form I of Sacubitril-Telmisartan obtained as per Example 7.
FIGURE 8. Modulated DSC plot of Sacubitril-Telmisartan (1:1) Amorphous Form.
FIGURE 9: DSC thermogram of crystalline Sacubitril-Telmisartan (1:1) Form I.
FIGURE 10: TGA/DTA analysis of crystalline Sacubitril-Telmisartan (1:1) Form I.
FIGURE 11: FT-IR spectra of Sacubitril.
FIGURE 12: FT-IR spectra of Telmisartan Form A. FIGURE 13: FT-IR spectra of amorphous Sacubitril-Telmisartan.
FIGURE 14: FT-IR spectra of crystalline Form I Sacubitril-Telmisartan.
DETAILED DESCRIPTION OF THE INVENTION
The principal object of the present invention is to provide processes for the preparation of crystalline form I and an amorphous form of Sacubitril-Telmisartan; amorphous solid dispersion of Sacubitril-Telmisartan and process for the preparation of the same.
Instrumentation Details:
Powder X-ray Diffraction (PXRD) The X-ray diffraction patterns of said polymorphs of the present invention were measured on BRUKER D8 Discover powder diffractometer equipped with goniometer of Q/2Q configuration and Lynx Eye detector. The Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 2Q range of 2.0°— 50.0°, 0.030° step size and 0.4 seconds step time. MDSC
The glass transition temperature (Tg) was measured on TA Q2000 of TA instruments with modulated DSC software. The sample was heated from 30 to 300°C at a heating rate of 5.0°C/min with modulation amplitude ±1.0°C, modulation period 60 sec and nitrogen purging at a flow rate of 50ml/min. Standard aluminum pans covered by lids with one pinhole was used. DSC
DSC was recorded using TA Q5000 of TA instruments. The experiments were performed at a heating rate of 10.0°C/min over a temperature range of 20°C— 300°C purging with nitrogen at
a flow rate of 50 ml/min. Standard aluminum pans covered by lids with five pinholes were used.
TGA
TGA was recorded using TA Q5000 of TA instruments. The experiments were performed at a heating rate of 10.0°C/min over a temperature range of 20°C-300°C purging with nitrogen at a flow rate of 25 ml/min. Standard aluminum pans covered by lids with five pin holes were used.
FT-IR
The FT-IR data was recorded using Perkin Elmer spectrum one instrument in the range of 400- 4000 cm 1 by using KBr pellets.
Water Content
Water content for Sacubitril-Telmisartan (1:1) amorphous complex and crystalline Sacubitril- Telmisartan (1:1) Form I were determined on Metrohm Karl-Fisher titrator (Model: 841 titrando) using dehydrated methanol and a 1:1 methanol-DMF mixture. For the determination of water content in sample, 40 ml of dehydrated methanol was placed in the titration vessel and titrated with standardized reagent to get the electrometric end point. 0.25 gram of sample were added, stirred for 1 minute and titrated to the end point with KF reagent. For each determination fresh methanol was used.
In one embodiment, Sacubitril-Telmisartan of the present invention is as shown below is a complex of Sacubitril-Telmisartan (1:1).
The amorphous solid dispersion of Sacubitril-Telmisartan is a complex of Sacubitril- Telmisartan and an excipient (1:1).
The present invention is directed to dual-acting compound where it constituent Sacubitril and Telmisartan molecules are linked via non-covalent bonding, or a supramolecular complex comprising said molecules, also described as mixed salts or cocrystals, depending on the degree
of transfer of the proton from the proton donor to the acceptor, linking the two constituent molecules by hydrogen bonding — known examples of such multi-drug, fixed dose combination products being Entresto (valsartan-Sacubitril) and Seglentis (1:1 tramadol hydrochloride-celecoxib complex) .
In one embodiment, the present invention provides amorphous form of Sacubitril-Telmisartan.
One embodiment of this invention is a solid phase comprising a 1:1 amorphous complex of Sacubitril and Telmisartan, characterized by a single glass transition in modulated DSC, a distinct halo-like PXRD pattern indicating an amorphous phase and significant shifts in the IR absorption bands compared to the constituent molecules- corresponding to strong hydrogen bonding interactions.
In one embodiment, the amorphous form of Sacubitril-Telmisartan disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.l & FIG 2.
In one embodiment, the present invention provides a process for the preparation of amorphous form of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril and Telmisartan in a suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous Sacubitril-Telmisartan.
According to the present invention, Sacubitril and Telmisartan are dissolved in a suitable solvent or mixtures thereof. The suitable solvent for dissolving includes, but not limited to polar solvents and non-polar solvents. Polar solvents such as methanol, ethanol, propanol, isopropanol, butanol, trifluroethanol, hexafluro-2-propanol, water, dimethyl sulfoxide and non polar solvents such as dichloromethane, toluene. Preferably mixture of solvents; more preferably mixture of methanol and dichloromethane. The suitable temperature for dissolving is selected from 20-35°C; preferably 23-27 °C.
Next, the solvent is removed from the above resulting Sacubitril-Telmisartan solution to isolate amorphous Sacubitril-Telmisartan. The solvent removal of the above embodiment may carry out according to the methods well known in the art, for example, by distillation, evaporation, spray drying, lyophilization, freeze drying or by agitated thin film drier.
In another embodiment, the present invention provides a process for the preparation of amorphous solid dispersion of Sacubitril-Telmisartan.
In one embodiment, the pharmaceutical excipient for the solid dispersion of Sacubitril- Telmisartan may include diluents, lubricants, binders, glidants, stabilizers, surface active agents, anti- adherents, opacifiers, solvents, colorants, lubricants, pigments, anti-foam agents, and polishing agents. In some embodiments, microcrystalline cellulose, polysorbate, mannitol, and hydroxypropyl alkylcellulose, hydroxypropyl alkylcellulose acetate succinate, hydroxypropyl alkylcellulose acetate succinate L-type M-type and H-type grades are found to be particularly useful excipients. Within the context of the present invention, the excipient or combinations of excipients may be included in the formulation.
In another embodiments, the preferable pharmaceutical excipients for the amorphous solid dispersion of Sacubitril-Telmisartan is ethyl cellulose, Plasdone S-630 and Povidone-K30.
In one embodiment, the amorphous solid dispersion of Sacubitril-Telmisartan and ethyl cellulose disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.3.
In one embodiment, the amorphous solid dispersion of Sacubitril-Telmisartan and Plasdone S- 630 disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.4.
In one embodiment, the amorphous solid dispersion of Sacubitril-Telmisartan and Povidone- K30 disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG
5.
In one more embodiment, the present invention provides a process for the preparation of amorphous solid dispersion of Sacubitril-Telmisartan (1:1).
In another embodiment, the present invention provides a process for the preparation of an amorphous solid dispersion of Sacubitril-Telmisartan comprising the steps of: a) taking Sacubitril; Telmisartan and a pharmaceutically acceptable excipient in suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous solid dispersion of Sacubitril-Telmisartan
According to the present invention, Sacubitril; Telmisartan and a pharmaceutically acceptable excipient are dissolved in a suitable solvent or mixtures thereof. The suitable solvent for dissolving includes, but not limited to polar solvents and non-polar solvents. Polar protic solvents such as methanol, ethanol, trifluroethanol, hexafluro-2-propanol, propanol, isopropanol, butanol, water, dimethyl sulfoxide and non-polar solvents such as dichloromethane, toluene, preferably mixture of solvents; more preferably mixture of methanol and dichloromethane. The suitable temperature for dissolving is selected from 20- 35°C; preferably 23-27 °C.
In one embodiment, the pharmaceutical excipient may include diluents, lubricants, binders, glidants, stabilizers, surface active agents, anti-adherents, opacifiers, solvents, colorants, lubricants, pigments, anti-foam agents, and polishing agents. In some embodiments, microcrystalline cellulose, polysorbate, mannitol, and hydroxypropyl alkylcellulose, hydroxypropyl alkylcellulose acetate succinate, hydroxypropyl alkylcellulose acetate succinate L-type, M-type and H-type grades are found to be particularly useful excipients. Within the context of the present invention, the excipient or combinations of excipients may be included in the formulation.
Examples of useful pharmaceutical excipients within the context of the present invention include starches, lactose, mannitol (for example, Pearlitol™ SD200), cellulose and cellulose derivatives, and confectioner's sugar. Different forms of lactose may be useful in the context of the present invention, for example, lactose monohydrate, lactose DT (direct tableting), and lactose anhydrous. Different forms of starches may be used in the context of the present invention, for example, maize starch, potato starch, rice starch, wheat starch, pre-gelatinized starch, starch 1500, starch 1500 LM grade, and fully pre-gelatinized starch. Examples of suitable cellulose compounds for use in the context of the present invention include crystalline celluloses, such as Ceolus™ KG-801, and a variety of Avicel™ celluloses (for example, PH- 101, PH-102, PH-301, PH-302, PH-F20, PHI-12, PH-114, and PH-112). Powdered celluloses may be used as well. Other useful cellulose derivatives include hydroxypropylcellulose (HPC examples include Klucel ™ LF and Klucel™ EXF), low-substituted hydroxypropylcelluloses (L-HPCS examples include LH-11, LH-21, LH-31, LH-22, LH-32, LH-20, LH-30, LH-32 and LH-33), hydroxypropyl alkyl cellulose (also called hypromellose or HPMC, HPMC-AS (hydroxypropyl alkylcellulose acetate succinate including L-type M-type and H-type grades)
one example is Methocel™). Other suitable binders/disintegrants include polyvinylpyrrolidones (also called povidone; examples include PVP-K25, PVP-K29, PVP- K30, and PVP-K90), copovidone (for example, Plasdone™ S-630). Other suitable excipients include powdered acacia, gelatin, guar gum, sodium starch glycolate, colloidal silicon dioxide, carbomers (for example, Carbopol™), alkylcelluloses, polymethacrylates, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, and crospovidones (for example, cross- linked povidone, Kollidon™ CL Polyplasdone™ XL, XI- 10, and INF- 10). Further examples of suitable excipients include sorbitan esters (for example, Span™), polyhydroxyethylenically- treated sorbitan esters (for example, Tween™), aliphatic alcohols and polyethylene glycol (PEG) ethers, phenol and PEG ethers, quaternary ammonium salts (e.g., cetyltrimethylammonium bromide), amine salts (for example, octadecylamine Hydrochloride), stearates (for example, glyceryl monostearates, polyoxyethylene mono stearates, ethylene glycol stearates, propylene glycol stearates, diethylene glycol stearates, glycerol stearates, sodium stearate, potassium stearate, ammonium stearate, calcium stearate, sodium stearate, triethenolamine stearate, zinc stearate, and magnesium stearate), sodium lauryl sulfate, magnesium lauryl sulfate, calcium and sodium soaps, sodium dioctylsulfosuccinate, sodium dodecylbenzenesulfonate, palmitic acid, talc, carnauba wax, silicate, silicon dioxide, hydrogenated vegetable oils and fats, stearic acid, and combinations thereof. Phospholipids (e.g., diacylphosphatidylglycerols, diaceylphosphatidylcholines, and diaceylphosphatidic acids, the precursors and derivatives thereof, such as soybean lecithin and egg yolk) may also be used. Examples of suitable pigments include titanium oxide, silicon dioxide, iron oxides, zinc oxide, and combinations thereof. Suitable plasticizers include, as examples, castor oil, diacetylated mono glycerides, dibutyl sebacate, diethyl phthalate, glycerin, polyethylene glycol, polyethylene glycol 6000, stearic acid, propylene glycol, triacetin, and triethyl citrate. Suitable basic inorganic salts of sodium, potassium, magnesium, and calcium (e.g., sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium carbonate, calcium carbonate, magnesium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, potassium hydrogen carbonate, potassium hydroxide, heavy magnesium carbonate, magnesium, [Mg6Al(0H)16 C03-4H20], aluminum hydroxide-magnesium, and [2.5MgO· A1203Ή20] may be include in the formulation as well.
Many of the excipients listed above can act in a multitude of functional roles (e.g., starches can act both as a disintegrates and a binder depending on the formulation) to dictate the final properties of the desired product. One of skill in the art will readily recognize these various
functional aspects of each excipient and be able to incorporate, without undue experimentation, an excipient, or combinations of excipients to achieve the desired final product.
In another embodiment, ethyl cellulose, Plasdone S-630 and Povidone-K30 have been found to particularly useful excipients for preparing an amorphous solid dispersion of Sacubitril and Telmisartan.
Next, the solvent is removed from the above resulting Sacubitril-Telmisartan solution to isolate amorphous Sacubitril-Telmisartan solid dispersion. The solvent removal of the above embodiment may carried out according to the methods well known in the art, for example, by distillation, evaporation, spray drying, lyophilization, freeze drying or by agitated thin film drier.
In one more embodiment, the present invention provides crystalline form I of Sacubitril- Telmisartan.
Yet another embodiment of this invention is a 1:1 crystalline complex of Sacubitril and Telmisartan designated as Form I, characterized by a single melting endotherm in DSC and a crystalline PXRD pattern, both distinct from either of the constituent molecules and significant shifts in the IR absorption bands compared to the constituent molecules-corresponding to strong hydrogen bonding interactions, and containing water in the range of 1.5% to 2.5% indicating that it is a hydrate, preferably a monohydrate.
In one embodiment, the crystalline form I of Sacubitril-Telmisartan disclosed herein may be characterized by PXRD pattern substantially as depicted in FIG.6 & FIG.7.
Within the context of the present invention, the crystalline form I of Sacubitril-Telmisartan disclosed herein may be characterized by PXRD spectrum having peaks 4.50, 16.53, 20.09, 24.32, 24.74 ±0.2° 2Q.
In one embodiment of the present invention, the crystalline form I of Sacubitril-Telmisartan disclosed herein may be further characterized by PXRD spectrum having peaks 4.50, 12.78, 16.53, 18.95, 20.09, 20.97, 24.32, 24.74, 25.71 ±0.2° 2Q.
In one more embodiment, the present invention also provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of:
a) taking Sacubitril-Telmisartan into a suitable solvent or mixtures thereof; and b) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
Within the context of the present invention, the Sacubitril-Telmisartan is taken into suitable solvent or mixtures thereof. The Sacubitril-Telmisartan of this embodiment may in an amorphous form and may further dissolved or suspended in suitable solvent or mixtures thereof. The suitable solvent for the dissolution or suspension is selected from organic solvents, but not limited to non-polar solvents such as diethyl ether, isopropyl ether, methyl tertiary butyl ether, cylcopentyl methyl ether, toluene, xylene or mixtures thereof. The reaction is maintained at 0 °C to reflux temperature, preferably at room temperature. The reaction mixture is stirred for 30 min to-24 hrs; preferably 1-5 hrs; more preferably 2-3 hrs.
Next, the solvent is removed by filtering from the above resulting Sacubitril-Telmisartan mixture to isolate the solid of Sacubitril-Telmisartan. The solid may be further processed by drying to obtain crystalline form I of Sacubitril-Telmisartan.
In one more embodiment, the present invention also a provides a process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril-Telmisartan into a first solvent or mixtures thereof; and b) optionally seeding with crystalline Form I seeds of Sacubitril-Telmisartan; c) adding a second solvent; and d) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
Within the context of the present invention, the Sacubitril-Telmisartan is dissolved into suitable first solvent and optionally seeded with Form I seeds and further added a second solvent and maintained the reaction for completion. After completion of the reaction, the reaction mass was filtered to isolate crystalline Form I of Sacubitril-Telmisartan. The suitable first and second solvents are selected from organic solvents. The first solvent is selected from alcoholic solvents such as methanol, ethanol, propanol, isopropanol; halogenated solvents selected from dichloromethane, trifluroethanol, trichloro ethanol, and hexafluroisopropanol. The second solvents selected from non-polar solvents such heptane, diethyl ether, isopropyl ether, cylcopentyl methyl ether; preferably; the suitable first solvent is dichloromethane and the second solvent is heptane.
The reaction is maintained at 0 °C to reflux temperature, preferably at room temperature. The reaction mixture is stirred for 30 min to-24 hrs; preferably 1-5 hrs; more preferably 2-3 hrs.
The Sacubitril-Telmisartan of this embodiment may in an amorphous form and may further dissolved or suspended in suitable solvent or mixtures thereof.
Next, the solvent is removed by filtering from the above resulting Sacubitril-Telmisartan mixture to isolate the solid of Sacubitril-Telmisartan. The solid may be further processed by drying to obtain crystalline form I of Sacubitril-Telmisartan.
DSC studies:
MDSC analysis (Figure 8) of the Sacubitril-Telmisartan (1:1) amorphous complex shows a single glass transition at Tg = 62.95°C, which indicates that it is a single, unique phase.
Similarly, DSC overlay (Figure 9) of crystalline Sacubitril-Telmisartan (1:1) Form I shows one endothermic peak at about 88°C. The later events seen in the thermogram of crystalline Sacubitril-Telmisartan (1:1) Form I may be attributed to the recrystallization of Telmisartan Form A.
TGA analysis:
TGA analysis of crystalline Sacubitril-Telmisartan (1:1) Form I (Figure 10) shows about 2.5% weight loss at around 80°C, which is matching with the water content determined by Karl Fischer titration (Table 1).
Water content:
The Sacubitril-Telmisartan (1:1) amorphous form and crystalline Sacubitril-Telmisartan (1:1) Form I were analyzed for water content by Karl-Fischer (KF) titration. The results are summarized in Table 1.
KF analysis of Sacubitril-Telmisartan (1:1) amorphous form shows the water content is around 1% whereas in crystalline Sacubitril-Telmisartan (1:1) Form I the water content is in the range of 1.5% to 2.5% which indicates that crystalline Sacubitril-Telmisartan (1:1) Form I is a hydrate and preferably, a monohydrate.
Table 1. Comparison of water content of Sacubitril-Telmisartan (1:1) amorphous form and crystalline Sacubitril-Telmisartan (1:1) Form I.
Table 1
FTIR spectra:
Comparison of the FTIR spectra of Sacubitril crystalline form (Figure 11), Telmisartan Form A (Figure 12), Sacubitril-Telmisartan (1:1) Amorphous form (Figure 13) and Sacubitril- Telmisartan Form I (Figure 14) reveals significant shifts in the wavenumbers for Sacubitril- Telmisartan (1:1) amorphous form and Sacubitril-Telmisartan (1:1) Form I corresponding to O-H, C=0 stretching vibrations in Telmisartan and N-H, C=0 (ester) and C=0 (amide) stretching vibrations in Sacubitril compared to that of native APIs (Refer Table 2). Table 2. The characteristic FT-IR data for Sacubitril crystalline form, Telmisartan form A, Sacubitril-Telmisartan Amorphous Form and Sacubitril-Telmisartan Form I.
Table 2
Based on the observations from FT-IR data, coupled with the unique thermal behavior of these two phases (amorphous form and Form I) and their distinct PXRD patterns further confirms the Sacubitril-Telmisartan (1:1) amorphous form and crystalline Sacubitril-Telmisartan (1:1) Form I are novel complexes. From water content data, the crystalline Sacubitril-Telmisartan (1:1) Form I is a hydrate, preferably a monohydrate.
Stability:
In yet another embodiment, the physical and chemical stability of Sacubitril-Telmisartan (1:1) amorphous form was determined by storing the samples at 5±3°C and 25°C and 60% relative humidity (RH) conditions for 9 months and the samples were analyzed by PXRD and HPLC Purity. The results are shown in below Table 3A. The Sacubitril-Telmisartan (1:1) amorphous form was found to be physically and chemically stable at 5±3°C and 25°C and 60% relative humidity (RH) conditions upto nine months. Table 3A- Summary of Sacubitril-Telmisartan amorphous form stability study.
In yet another embodiment, the physical and chemical stability of crystalline Sacubitril- Telmisartan (1:1) Form I was determined by storing the samples at 5±3°C and 25°C and 60% relative humidity (RH) conditions for 3 months and the samples were analyzed by PXRD and HPLC Purity. The results are shown in below Table 3B. The crystalline Sacubitril-Telmisartan (1:1) Form I was found to be physically and chemically stable at 5±3°C and 25°C and 60% relative humidity (RH) conditions upto three months.
Table 3B- Summary of Sacubitril-Telmisartan Form I stability study.
In view of the above description and the examples below, one of ordinary skill in the art will be able to practice the invention as claimed without undue experimentation. The foregoing will be better understood with reference to the following examples that detail certain procedures for the preparation of molecules according to the present invention. All references made to these examples are for the purposes of illustration. The following examples should not be considered exhaustive, but merely illustrative of only a few of the many aspects and embodiments contemplated by the present disclosure.
Examples:
Example 1: Amorphous Sacubitril-Telmisartan (1:1):
4 g of Sacubitril and 5g of Telmisartan were dissolved in a mixture of 15 mL of methanol and 60 mL of dichloromethane at 25±2°C. The resulting clear solution was filtered through hyflo. The hyflo bed washed with the mixture of 2 mL methanol and 8mL dichloromethane and subjected to spray drying in a laboratory Spray Dryer (Model Buchi-290) with feed rate of the solution 5ml/min and inlet temperature at 65 °C to yield amorphous form of Sacubitril- Telmisartan (1:1). Yield: 6.2 g.
Example 2:Amorphous Sacubitril-Telmisartan (1:1):
Dissolve 0.08 g of Sacubitril and 0.1 g of Telmisartan were dissolved in a mixture of 0.4 mL of methanol and 1.6 mL of dichloromethane at 25±2°C. The resulting clear solution was distilled completely under vacuum in laboratory rotary evaporator to yield amorphous form of Sacubitril-Telmisartan (1:1). Yield: 0.15 g.
Example 3: Amorphous solid dispersion of Sacubitril-Telmisartan (1:1):
0.08 g of Sacubitril, 0.1 g of Telmisartan and 0.18 g of ethyl cellulose were dissolved in a mixture of 0.4 mL of methanol and 1.6 mL of dichloromethane at 25±2°C. The resulting clear solution was distilled completely under vacuum in laboratory rotary evaporator to yield 1 : 1 (w/w) amorphous solid dispersion of Sacubitril-Telmisartan with ethyl cellulose. Yield: 0.25 g·
Example 4: Amorphous solid dispersion of Sacubitril-Telmisartan (1:1):
0.08 g of Sacubitril, 0.1 g of Telmisartan and 0.18 g of Plasdone S-630 were dissolved in a mixture of 0.4 mL of methanol and 1.6 mL of dichloromethane at 25±2°C. The resulting clear solution was distilled completely under vacuum in laboratory rotary evaporator to yield 1 : 1 (w/w) amorphous solid dispersion of Sacubitril-Telmisartan with Plasdone S-630. Yield: 0.25 g·
Example 5: Amorphous solid dispersion of Sacubitril-Telmisartan (1:1):
0.08 g of Sacubitril, 0. lg of Telmisartan and 0.18 g of PVP K30 were dissolved in a mixture of 0.6 mL of methanol and 2.4 mL of dichloromethane at 25±2°C. The resulting clear solution was distilled completely under vacuum in laboratory rotary evaporator to yield 1:1 (w/w) amorphous solid dispersion of Sacubitril-Telmisartan with PVP K30. Yield: 0.13 g.
Example 6: Crystalline Form I of Sacubitril-Telmisartan (1:1):
10 g of Amorphous form of Sacubitril-Telmisartan was dissolved in 140 mL of toluene at 25±2°C. The resulting clear solution was maintained under stirring for 2h at 25±2°C. The product obtained was filtered, washed with 40 mL of toluene and suck-dried for 30min. The wet product was further dried under vacuum at 55±2°C for 15h to yield novel crystalline Sacubitril-Telmisartan (1:1) Form I. Yield: 9.6 g.
Example 7: Crystalline Form I of Sacubitril-Telmisartan (1:1):
20 g of amorphous form of Sacubitril-Telmisartan was suspended in 400 mL of isopropyl ether at 25±2°C and stir the reaction mass at 25±2°C for 2 h. The product obtained was filtered, washed with 80 mL of isopropyl ether and suck-dried for 30 min. The wet product was further dried under vacuum at 55±2°C for 15h to yield novel crystalline Sacubitril-Telmisartan (1:1) Form I. Yield: 19.2 g.
Example 8: Crystalline Form I of Sacubitril-Telmisartan (1:1):
100 mg of Sacubitril-Telmisartan amorphous form was dissolved in 1 mL xylene at 25±2°C. Stir the reaction mass at 25±2°C for 2 h. The product obtained was filtered and suck-dried for 30 minutes to yield novel crystalline Sacubitril-Telmisartan Form I. Yield: 80 mg.
Example 9: Crystalline Form I of Sacubitril-Telmisartan (1:1):
50 g of Sacubitril-Telmisartan amorphous form was dissolved in 150 mL of dichloromethane at 25±2°C and cooled to 2±2°C, then added 2.5g of Sacubitril-Telmisartan Form I seeds and added 1L of n-heptane at 2±2°C for 40 minutes. The reaction mass was maintained under stirring at 2±2°C for 17 h, filtered, washed with 100 mL of chilled heptane and dried under vacuum at 50 °C for 48h. The resulting solid was identified as novel crystalline Sacubitril- Telmisartan Form I. Yield: 48.8 g.
Claims
1. A crystalline form I of Sacubitril-Telmisartan having PXRD peaks 4.50, 16.53, 20.09, 24.32 and 24.74 ±0.2° 2Q.
2. A crystalline form I of Sacubitril-Telmisartan characterized by PXRD pattern substantially as depicted in FIG.6.
3. A process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril-Telmisartan into a suitable solvent or mixtures thereof; and b) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
4. The process as claimed in claim 3, wherein the suitable solvent is selected from diethyl ether, isopropyl ether, methyl tertiary butyl ether, cylcopentyl methyl ether, toluene and xylene.
5. A process for the preparation of crystalline form I of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril-Telmisartan into a first solvent or mixtures thereof; and b) optionally seeding with crystalline Form I seeds of Sacubitril-Telmisartan; c) adding a second solvent; and d) filtering the solvent to isolate crystalline form I of Sacubitril-Telmisartan.
6. The process as claimed in claim 5, wherein the first solvent is selected from methanol, ethanol, propanol, isopropanol; dichloromethane, trifluroethanol and hexafluro-2- propanol; second solvent is selected from heptane, diethyl ether, isopropyl ether and cylcopentyl methyl ether.
7. An amorphous form of Sacubitril-Telmisartan.
8. An amorphous form of Sacubitril-Telmisartan characterized by PXRD pattern substantially as depicted in FIG.l.
9. A process for the preparation of amorphous form of Sacubitril-Telmisartan comprising the steps of: a) dissolving Sacubitril and Telmisartan in a suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous Sacubitril-Telmisartan.
10. The process as claimed in claim 9, wherein solvent is selected from polar solvent, non polar solvent or mixtures thereof.
11. The process as claimed in claim 10, wherein the polar solvent is selected from methanol, ethanol, propanol, isopropanol, butanol, trifluroethanol, hexafluro-2- propanol, water, dimethyl sulfoxide; non-polar solvent is selected from dichloromethane and toluene.
12. An amorphous solid dispersion of Sacubitril-Telmisartan with at least one pharmaceutically acceptable excipient.
13. The solid dispersion of amorphous Sacubitril-Telmisartan as claimed in claim 12, wherein the pharmaceutically acceptable excipient selected from ethyl cellulose, Plasdone S-630 and Povidone-K30.
14. A process for the preparation of an amorphous solid dispersion of Sacubitril- Telmisartan comprising the steps of: a) taking Sacubitril; Telmisartan and a pharmaceutically acceptable excipient in suitable solvent or mixtures thereof; and b) removing the solvent to isolate amorphous solid dispersion of Sacubitril- Telmisartan.
15. The process as claimed in claim 14, wherein the pharmaceutically acceptable excipient selected from ethyl cellulose, Plasdone S-630 and Povidone-K30.
16. The process as claimed in claim 14, wherein the solvent is selected from polar and non polar solvents or mixtures thereof.
17. The process as claimed in claim 16, wherein the polar solvent is selected from methanol, ethanol, propanol, isopropanol, butanol, trifluroethanol, hexafluro-2- propanol, water, dimethyl sulfoxide; non-polar solvent selected from dichloromethane and toluene.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141018214 | 2021-04-20 | ||
| IN202141018214 | 2021-04-20 | ||
| IN202141026619 | 2021-06-15 | ||
| IN202141026619 | 2021-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022224274A1 true WO2022224274A1 (en) | 2022-10-27 |
Family
ID=81748567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2022/050374 WO2022224274A1 (en) | 2021-04-20 | 2022-04-19 | Polymorphic forms of sacubitril-telmisartan (1:1) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022224274A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114723A1 (en) * | 2022-11-30 | 2024-06-06 | 越洋医药开发(广州)有限公司 | Cocrystal of enkephalinase inhibitor and angiotensin ii receptor antagonist, and preparation method therefor and use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5591762A (en) | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
| US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
| US8877938B2 (en) | 2005-11-09 | 2014-11-04 | Novartis Pharmaceuticals Corporation | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
| CN106466481A (en) * | 2015-08-19 | 2017-03-01 | 叶莉 | Sartans and NEPi complex |
| IN201741004255A (en) * | 2017-02-06 | 2018-08-10 |
-
2022
- 2022-04-19 WO PCT/IN2022/050374 patent/WO2022224274A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591762A (en) | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
| US8877938B2 (en) | 2005-11-09 | 2014-11-04 | Novartis Pharmaceuticals Corporation | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
| CN106466481A (en) * | 2015-08-19 | 2017-03-01 | 叶莉 | Sartans and NEPi complex |
| IN201741004255A (en) * | 2017-02-06 | 2018-08-10 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114723A1 (en) * | 2022-11-30 | 2024-06-06 | 越洋医药开发(广州)有限公司 | Cocrystal of enkephalinase inhibitor and angiotensin ii receptor antagonist, and preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884630B2 (en) | Heterocyclic compounds and their uses | |
| US7943779B2 (en) | Process for the preparation of olmesartan medoxomil | |
| JP6952707B2 (en) | Solid dispersant comprising an sGC stimulant | |
| EP1513528B1 (en) | Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride | |
| US11117875B2 (en) | Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod | |
| US11286259B2 (en) | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof | |
| EP1646403A2 (en) | Pharmaceutical composition for solubility enhancement of hydrophobic drugs | |
| JP2019048830A (en) | Heterocyclic compounds and their uses | |
| WO2022224274A1 (en) | Polymorphic forms of sacubitril-telmisartan (1:1) | |
| US20240208931A1 (en) | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof | |
| AU2020216925B2 (en) | Sulcardine salts | |
| US20190083627A1 (en) | Pharmaceutical Composition Containing Tacrolimus and Preparation Methods Thereof | |
| US10479782B2 (en) | Forms of lumacaftor and processes for the preparation thereof | |
| WO2020121326A1 (en) | Amorphous (rac)-tramadol.hcl-celecoxib (1:1) | |
| WO2014013465A2 (en) | Salts and hydrates of antipsychotics | |
| JP2018515566A (en) | Pharmaceutical composition | |
| US20150328215A1 (en) | Stable amorphous raltegravir potassium premix and process for the preparation thereof | |
| KR20230155504A (en) | (4S)-24-Chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1) Pharmaceutical dosage forms comprising -pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphan-74-carboxamide | |
| US10822309B2 (en) | Crystalline form of Eluxadoline | |
| JP2004525969A (en) | 3,7-diazabicyclo [3.3.1] preparation as antiarrhythmic compound | |
| US20220098192A1 (en) | A process for the preparation of trametinib acetic acid solvate | |
| KR20110005974A (en) | A sustained release preparation of indobufen and stereo isomer and isolating method of stereo isomer thereof | |
| EA042489B1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING SACUBITRIL AND VALSARTAN | |
| KR20050038858A (en) | Thermodynamic stable amorphous torasemide solid dispersions and pharmaceutical composition comprising same and method for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22724272 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22724272 Country of ref document: EP Kind code of ref document: A1 |